Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2026)
Heron Therapeutics' (HRTX) quarterly Other Non-Current Liabilities came in at $4.9 million in Q1 2026, up 622.73% YoY from $682000.0 in Q1 2025, and up 2.52% on a QoQ basis from $4.8 million in Q4 2025.
Heron Therapeutics (HRTX) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 5 years of Other Non-Current Liabilities data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 622.73% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 622.73% YoY) and the FY2025 annual result came in at $4.8 million, up 681.79% from the prior year.
- Other Non-Current Liabilities rose to $4.9 million in Q1 2026, from $4.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q1 2026 to a low of $241000.0 in Q1 2022.
- A 5-year average of $1.1 million and a median of $241000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities changed 0.0% — and 2025, when it surged 1847.72%.
- Tracing HRTX's Other Non-Current Liabilities over 5 years: stood at $241000.0 in 2022, then changed by 0.0% to $241000.0 in 2023, then jumped by 155.19% to $615000.0 in 2024, then jumped by 681.79% to $4.8 million in 2025, then rose by 2.52% to $4.9 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $4.8 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.06 Mn |
| Mar 31, 2026 | 4.93 Mn |
| Dec 31, 2025 | 4.81 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 747,000.00 |
| Mar 31, 2025 | 682,000.00 |
| Dec 31, 2024 | 615,000.00 |
| Sep 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 241,000.00 |
| Sep 30, 2023 | 241,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 241,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | 241,000.00 |